Full-Time
Biotech startup developing innovative medicines
$252k - $275.5k/yr
Expert
San Bruno, CA, USA + 1 more
More locations: New York, NY, USA
Hybrid
Minimum of 3 days a week of onsite presence required.
Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking platform to visualize protein movements in living cells, combined with artificial intelligence and automation for precise molecular interaction analysis. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. Eikon stands out from competitors by focusing on the dynamic aspects of biology rather than static chemical processes.
Company Size
201-500
Company Stage
Series D
Total Funding
$1.1B
Headquarters
Hayward, California
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
401(k) Company Match
Medical (premiums covered by Eikon at 95%)
Dental Insurance
Vision Insurance
Mental Health Support
Unlimited Paid Time Off
Paid Holidays
Life Insurance
Enhanced Parental Leave
Daily subsidized lunch program
Eikon Therapeutics Inc to spend $350.7 Million to expand in Millbrae California. Eikon Therapeutics Inc to spend $350.7 Million to expand in Millbrae California.Millbrae, California — According to state and local development sources, Eikon Therapeutics Inc. plans to invest $350,700,000.00 to build out new space in Millbrae. The company plans to occupy the new space in Millbrae, on or about May 1, 2027. According to the company website Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikons discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells
Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.
Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a
Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.